Invesco Ltd. Infla Rx N.V. Transaction History

Invesco Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$1.25 - $2.75 $195,370 - $429,814	156,296 Added 95.33%	320,246 $522,000
Q3 2023 Nov 13, 2023	BUY	$2.66 - $4.33 $19,532 - $31,795	7,343 Added 4.69%	163,950 $488,000
Q2 2023 Aug 11, 2023	BUY	$2.05 - $6.1 $189,854 - $564,933	92,612 Added 144.72%	156,607 $698,000
Q1 2023 May 12, 2023	BUY	$1.66 - $3.1 $15,746 - $29,406	9,486 Added 17.4%	63,995 $124,000
Q4 2022 Feb 13, 2023	SELL	$2.11 - $3.25 $454,422 - $699,939	-215,366 Reduced 79.8%	54,509 $168,000
Q3 2022 Nov 14, 2022	BUY	$1.32 - $3.14 $211,050 - $502,045	159,887 Added 145.37%	269,875 $712,000
Q2 2022 Aug 15, 2022	SELL	$0.78 - $1.9 $90,965 - $221,581	-116,622 Reduced 51.46%	109,988 $159,000
Q1 2022 May 16, 2022	BUY	$1.83 - $4.48 $123,001 - $301,118	67,214 Added 42.17%	226,610 $415,000
Q4 2021 Feb 14, 2022	BUY	$2.35 - $5.58 $374,580 - $889,429	159,396 New	159,396 $759,000

13.2M

5.2K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $61M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.